Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCentene Ambetter Formulary Coverage & PA Update | …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentCentenePolicy AMB25-AHS-C-00023-OH

    Ambetter Formulary (Prescription Drug List) — Coverage Criteria

    Customize your policy alerts

    Sign up for Centene Policy AMB25-AHS-C-00023-OH alerts

    Get alerted when Policy AMB25-AHS-C-00023-OH changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document governs the Ambetter prescription drug formulary (January 1, 2026) including coverage tiers, prior authorization, step therapy, quantity and age limits, specialty drug routing, and limits for opioid prescriptions; it affects providers and members served under the Ambetter/Centene prescription drug benefit.

    Policy Summary
    PayerCentene (Ambetter)
    PolicyAmbetter Formulary (Prescription Drug List) — Coverage Criteria
    Policy CodePolicy AMB25-AHS-C-00023-OH
    Change TypeNo material changes
    Effective DateJan 1, 2026
    Next Review Date
    Key ActionProviders must submit a Prior Authorization form for non-formulary drugs; urgent requests will be answered within 24 hours and non-urgent within 72 hours once complete information is received.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2026Formulary year/effective
    Tier 0-4Copay tiers described
    7-dayOpioid new-start limit
    24/72 hrsPrior auth response
    May applySpecialty fill requirement
    severalEntries with PA

    Formulary Coverage Criteria

    Formulary tier coverage

    Formulary coverage is tiered and may include limits or requirements; coverage and prior authorization rules apply as described.

    Formulary tiering and specialty: Drugs are categorized into Tier 0, Tier 1A, Tier 1B, Tier 2, Tier 3 and Tier 4 with differing copayment levels; specialty-tier (Tier 4) drugs may require fulfillment at participating specialty or hemophilia network pharmacies.

    Tier descriptions and specialty fill requirements provided.

    Prior Authorization — Non-Formulary Drugs

    Non-formulary drugs require prior authorization when requested as exceptions.

    Non-formulary prior authorization: Provider must submit a completed Prior Authorization form for non-formulary drugs; urgent requests will be responded to within 24 hours and non-urgent requests within 72 hours once all necessary information is received.

    Denial notices will explain reasons or identify missing information.

    Policy Summary
    PayerCentene (Ambetter)
    PolicyAmbetter Formulary (Prescription Drug List) — Coverage Criteria
    Policy CodePolicy AMB25-AHS-C-00023-OH
    Change TypeNo material changes
    Effective DateJan 1, 2026
    Next Review Date
    Key ActionProviders must submit a Prior Authorization form for non-formulary drugs; urgent requests will be answered within 24 hours and non-urgent within 72 hours once complete information is received.
    SourceLink
    On This Page
    Formulary Coverage CriteriaCoding, Quantity & Age LimitsProvider Requirements & Denial RisksInitial Therapy Limits & GuidanceStep Therapy RequirementsQuantity Limit Examples and EnforcementSpecialty, Infusion & Fulfillment NotesFormulary Abbreviations & DefinitionsBackground & Scope

    Opioid limits (new starts)

    Opioid prescribing for new starts is limited as specified.

    Opioid new-start limits: New opioid starts are limited to a 7-day supply; up to two 7-day fills are allowed during any 28-day period and up to a total of 28 non-consecutive days in any 90-day period; fills exceeding these limits require Prior Authorization.7-day supply; max two 7-day fills per 28 days; max 28 non-consecutive days per 90 days

    Limit applies cumulatively to all opioid medications listed.

    Formulary restrictions (per-product)

    Coverage and restrictions are specified per listed product and include one or more of the following conditions applied:

    Per-product restrictions: Each product entry lists a formulary Tier and may include one or more utilization controls such as Quantity Limits (QL), Prior Authorization (PA), Specialty distribution (SP), Step Therapy (ST) or New-start supply limits.

    See individual product lines for exact QL/PA/ST/SP and new-start language.

    Covered with criteria

    Products listed with a Tier and QL are covered subject to the specified quantity limits and any PA/SP requirements.

    Formulary coverage node: A product is covered when dispensed within its formulary Tier and within the listed Quantity Limit (QL); any indicated Prior Authorization (PA) or Specialty (SP) requirement must be met for coverage to apply.per-product QL values

    Individual line items define the exact QL, PA, SP and any age limits (AL).

    Formulary tier and utilization management

    Coverage is tier-based with utilization management controls; specific coverage is indicated by Tier = X and modifiers such as QL, PA, SP, and AL.

    Tiered coverage with utilization controls: Each drug entry lists a tier (e.g., Tier = 1B, 2, 3, 4) and may include Quantity Limits (QL), Prior Authorization (PA), Specialty Pharmacy routing (SP), and Age Limits (AL); these modifiers govern coverage and claims processing.

    Providers must follow per-product modifiers when submitting claims or PA requests.

    Formulary coverage indicators

    Coverage and utilization controls are indicated by tier, quantity limits (QL), prior authorization (PA) and specialty pharmacy (SP) flags for listed drugs.

    Formulary control flags: Each drug entry includes tiering and may include QL, PA, or SP flags; entries marked with these flags may require prior authorization or be subject to quantity/age limits to be payable.

    No additional clinical criteria are listed in this excerpt; PA indicates further review is required.

    Formulary coverage with conditions

    Coverage and restrictions are listed by formulary entries — products are assigned tiers and may include QL and PA conditions.

    Formulary entry coverage: A drug listed with a Tier is covered according to that tier, subject to any Quantity Limits (QL) and Prior Authorization (PA) flags shown for that specific formulation.see QL values per product

    PA flags indicate additional documentation/authorization required prior to coverage.

    Age-limited topical immunomodulators

    Age and authorization restrictions apply to topical immunomodulators and tacrolimus formulations.

    Age and PA requirements: Pimecrolimus is listed with QL(3 GM daily) and an age limit of at least 2 years; tacrolimus topical ointment is listed with AL(At least 2 yrs old) and requires Prior Authorization (PA).AL(At least 2 yrs old); QL(3 GM daily)

    Prescribers must confirm patient age and obtain PA where indicated prior to dispensing.

    The Ambetter Formulary is a guide to covered brand and generic drugs but is not a complete list of covered medications. Not all dosage forms or strengths may be covered and coverage can depend on the member's specific benefit plan. Formulary entries use tier assignments (e.g., Tier 0–4) and may include utilization controls such as Quantity Limits (QL), Prior Authorization (PA), Step Therapy (ST), specialty routing (SP), and age limits (AL); coverage is conditional on meeting the listed tier and any modifiers shown for the product.

    Within the excerpt there are no standalone sections that explicitly list broad programmatic exclusions; entries are presented as tiers with per-product flags (e.g., QL, PA, AL). The document therefore does not state blanket ‘excluded’ categories in this extract — instead, coverage limitations are expressed on a product-by-product basis.

    The excerpt does not present explicit clinical exclusions beyond the utilization controls shown for individual products. Restrictions that appear are primarily quantity limits (QL), prior authorization (PA), and initial-therapy/new-start constraints rather than diagnostic or indication-based exclusions.

    This formulary extract does not contain a dedicated list of drugs labeled as ‘Not Covered.’ Instead, it provides tier assignments and product-level limits (QL, PA, AL) that govern coverage; specific benefit designs may further restrict coverage as noted in the general formulary guidance.

    Some antimalarial products are restricted to malaria treatment only. For example, atovaquone-proguanil is indicated as “Covered for malaria treatment only” with QL(12 EA per fill) and a Limit: 1 fill every 180 days (per retail and mail entries).

    Reiterating the excerpt’s format: there are no explicit programmatic exclusions stated here. Coverage constraints are communicated by per-product tiering and utilization markers (e.g., QL, PA, AL) rather than general exclusion statements in this extract.

    For pancreatic enzyme (pancrelipase) products listed (e.g., CREON, ZENPEP), the excerpt notes that Non‑FDA approved uses require Prior Authorization. Providers should therefore expect PA to be required when requesting coverage for indications or formulations not described on the product labeling.

    There are no explicit statements in the provided excerpt that any drugs or uses are labeled as Not Medically Necessary. The extract conveys utilization controls (QL/PA/ST) but does not include NMN determinations in the shown lines.

    Consistent with other segments of the extract, the document does not include discrete ‘Not Medically Necessary’ determinations within the shown lines. Coverage decisions appear to be managed by PA, QL, AL, and tier flags rather than explicit NMN entries in this excerpt.

    As noted above, the excerpt contains no explicit NMN statements. Absent product-specific PA or QL flags, the listing indicates conditional coverage by tier and utilization controls rather than explicit denials for medical necessity in the extract.

    Certain unitized formulations of pancreatic enzyme products (ZENPEP entries and similar unit listings) explicitly tie Non‑FDA approved uses to prior authorization requirements in the extract. Where the entry indicates non‑FDA use, a PA is required before coverage will be considered.

    Coding, Quantity & Age Limits

    Formulary product entriesmixed
    No codes listed
    Formulary product entries (note)mixed
    no billing codesThis section lists drug product lines, tiers and utilization controls but contains no CPT/HCPCS/ICD/NDC billing codes in the excerpt.
    Formulary product listing (no billing codes)mixed
    no CPT/HCPCS/ICD codes presentThis excerpt lists drug products, tiers and quantity/PA limits but does not include procedural or diagnosis codes.
    Formulary utilization codes and indicatorsmixed
    QL(1 EA daily)Quantity limit: 1 each daily (appears for multiple drugs)
    QL(2 EA daily)Quantity limit: 2 each daily (appears for carbidopa-levodopa, olanzapine tabs, etc.)
    QL(0.072 EA daily)Quantity limit example for long-acting injectables (PERSERIS PRSY, risperidone microspheres)
    PAPrior authorization required
    SPSpecialty pharmacy required
    AL(At least 18 yrs old)Age limit: at least 18 years old
    QL(30 ML daily)Quantity limit in milliliters (example for dibenzapines entry)
    QL(6 EA daily)Quantity limit: 6 each daily (appears for clozapine TBDP 12.5 MG, 150 MG)
    QL(0.036 ML daily)Quantity limit in mL (haloperidol decanoate)
    Limit fill every 90 days; QL(10 EA per fill retail; 10 per fill mail); 1 max fill(s) per 90 day(s) retailFill-interval and per-fill limit language (appears for zidovudine and other agents)
    Formulary entries (no billing codes)mixed
    noneNo CPT/HCPCS/ICD-10/NDC codes present in this excerpt; drug product names and dosage forms only.
    Digestive enzyme product identifiersNDC | mixed
    CREON CPEPCREON pancreatic enzyme product entries with tiering and note: Non-FDA approved uses require Prior Authorization.
    ZENPEP CPEP 252600 UNIT-189600 UNIT-60000 UNITZENPEP unitized pancreatic enzyme product entries (various unit sizes) with Non-FDA approved uses require Prior Authorization.
    Diuretic and related oral product identifiersNDC | mixed
    chlorthalidone 25 MG, 50 MGlisted under Thiazides and Thiazide-Like Diuretics
    hydrochlorothiazide TABSlisted under Conditions and Blood Pressure
    acetazolamide CP12 / TABS 125 MGcarbonic anhydrase inhibitor entries with QL values
    Age and quantity limits examples
    Stimulant QL examplesQL(1 EA daily); QL(2 EA daily); QL(3 EA daily); QL(280 ML per 56 days)
    Minimum age examplesAL(At least 6 yrs old); AL(At least 12 yrs old); AL(At least 18 yrs old)
    Lisdexamfetamine noteQL(1 EA daily); ST (step therapy may apply)
    Opioid new-start supply — 7-day new-start limit
    New-start opioid supply limitNew starts limited to 7-day supply (applies cumulatively to all opioid medications)
    Allowed fills per 28 daysAllow up to two 7-day fills during any 28-day period
    90-day cumulative capUp to a total of 28 non-consecutive days supply in any 90-day period; fills exceeding require Prior Authorization
    Example quantity thresholds
    Small-dose biologic QL exampleQL(0.143 EA daily) — adalimumab presentations (package or per 180 days also noted)
    Injectable per-period exampleQL(3.6 ML per 28 day(s) retail; 4 ML per 28 days mail) — ACTEMRA ACTPEN/SOLN examples
    Large-volume solution exampleQL(40 ML per 28 day(s)) — ACTEMRA SOLN 200 example
    New-start supply limit — value summary
    New-start supply value summary7 day(s) — initial prescriptions for listed opioid products limited to a 7-day supply unless authorized
    Documentation for longer supplyFills exceeding 7-day new-start limits require Prior Authorization (providers should document justification)
    Cumulative applicationLimit applies cumulatively to all opioid medications filled
    Quantity limits (examples)
    Common daily QL examplesQL(2 EA daily); QL(6 EA daily); QL(12 EA daily)
    ML-based QL examplesQL(50 ML daily); QL(30 ML daily); QL(37.5 ML daily)
    Concentration/volume QL examplesQL(0.146 ML daily); QL(0.286 ML daily)
    Examples of quantity limits
    Starter pack / per-period limits1 max fill(s) per 180 day(s) retail — ELIQUIS DVTIPE STARTER PACK example
    Large suspension QLQL(900 ML per 30 day(s) retail; 900 ML per 30 days mail) — rivaroxaban suspension
    Enoxaparin QL examplesQL(6 ML daily) — enoxaparin 300 mg/3 mL; QL(2 ML daily) — select SOSY strengths
    Quantity limits examples — additional QL examples
    Large-volume injectable QLQL(6 ML daily) — enoxaparin sodium SOLN IJ 300 MG/3ML example
    Per-180-day QLQL(7.2 ML per 180 day(s)) — fondaparinux 10 MG/0.8 mL example
    Rescue/CNS agent QLQL(10 EA per 30 days) — NAYZILAM example; QL(60 ML daily) — VALTOCO 15 mg dose example
    Quantity limits examples — topical and oral examples
    Topical QL examples (common)QL(15 GM per 30 days); QL(60 GM per 30 days); QL(1 GM daily) — topical acne/topical examples
    Clotrimazole topical limitsQL(4.5 GM daily); Limit 1 Fill per 180 days; 1 max fill(s) per 180 day(s) retail
    Isotretinoin topical/oral exampleQL(60 GM per 30 day(s) retail; 60 GM per 30 days mail) — isotretinoin (10/20 mg) topical-related entry
    Quantity and age limits examples — mixed examples in excerpt
    Vancomycin oral QLQL(4 EA daily; 40 EA per fill retail) — vancomycin HCl caps example
    XIFAXAN (rifaximin) course limitsQL(3 EA per 3 day(s) retail; 9 EA per 3 days mail); AL(At least 12 yrs old); PA
    Atovaquone-proguanil (malaria) limitsQL(12 EA per fill retail; 12 per fill mail); Limit 1 fill every 180 days — covered for malaria treatment only
    Quantity limits examples — further QL examples extracted
    Hydroxychloroquine QLQL(3 EA daily) — hydroxychloroquine sulfate 200 mg example
    Ruxience QLQL(0.0089 EA daily) — RUXIENCE example
    TAGRISSO QLQL(2 EA daily) — TAGRISSO 40 mg example
    AL — Age Limit definition with examples
    AL (Age Limit) definitionAL = Age Limit. Some drugs are only covered for certain ages (e.g., AL(At least 12 yrs old); AL(At least 2 yrs old)).
    Topical AL examplesPimecrolimus and tacrolimus topical ointments list AL(At least 2 yrs old); many acne topicals list AL(At least 12 yrs old)
    Usage for PA/QL requestsProviders should document patient age when submitting PA where AL is noted
    Quantity limits examples — assorted QL values
    Assorted QL valuesQL(1 EA daily); QL(2 EA daily); QL(75 ML); QL(37.5 ML daily); QL(6 ML daily)
    Hemangeol / pediatric liquid exampleQL(75 ML) — HEMANGEOL SOLN PO example
    Pulmonary hypertension solution QLQL(6 ML daily) — sildenafil (pulmonary hypertension) solution example
    Age limits (AL) — at least 12 yrs old noted for multiple topical products
    Topical age floor (12 yrs) repeatedAL(At least 12 yrs old) — appears multiple times across topical acne/dermatologic product entries
    Pimecrolimus / tacrolimus age limitAL(At least 2 yrs old) — pimecrolimus and tacrolimus topical entries
    Imiquimod QL exampleQL(12 EA per fill retail; 12 per fill mail) — imiquimod 5%
    Example quantity limits — topical QL examples
    Topical per-day QL samplesQL(3.34 ML daily); QL(3 GM daily); QL(3.5 GM daily); QL(4 GM daily)
    Fluocinonide / fluticasone examplesQL(2 GM daily); QL(6 ML daily) — fluocinonide and fluticasone topical examples
    Betamethasone dipropionate examplesQL(3 GM daily); QL(3.5 GM daily); QL(4 ML daily) — betamethasone dipropionate formulations

    Provider Requirements & Denial Risks

    Prior Authorization

    Submit PA for non‑formulary drugs

    Providers must complete and submit the Ambetter Prior Authorization form for non‑formulary drug requests; urgent requests will be answered within 24 hours and non‑urgent requests within 72 hours after all required information is received.

    • Submit the completed Prior Authorization form to Ambetter.
    • Expect response: urgent = 24 hours; non‑urgent = 72 hours (unless state law requires faster).
    Prior Authorization

    Obtain PA for specialty/biologic agents

    Many biologic and specialty agents listed on the formulary (for example multiple ADALIMUMAB presentations, ACTEMRA, ENBREL) are annotated with 'PA' and require prior authorization before coverage will be provided.

    • Obtain PA prior to dispensing for biologic/specialty products shown with 'PA'.
    • Package/quantity limits (e.g., package(s) per 180 days) may be enforced with PA requests.
    Prior Authorization

    PA required for opioid entries

    Opioid-containing products and many analgesic entries show PA or new‑start constraints; where 'PA' is indicated, providers must secure prior authorization before coverage.

    • New opioid starts are limited to a 7‑day supply unless authorized (see new‑start limits).
    • If a listed opioid shows 'PA' obtain prior authorization before dispensing.
    Prior Authorization

    Get PA when 'PA' flag or max‑fill shown

    Products explicitly annotated with 'PA' (and any shown maximum‑fill language) require prior authorization before the payer will provide coverage for that item.

    • Check the formulary line for 'PA' or 'SP; PA' and obtain PA prior to dispensing.
    • Observe any max‑fill or per‑period limits when preparing PA documentation.
    Prior Authorization

    Request PA for listed high‑cost/specialty products

    Selected high‑cost or specialty agents in the list (examples include enoxaparin presentations, NAYZILAM, VALTOCO, SPRAVATO) are flagged 'PA' — providers must request prior authorization for these products.

    • Confirm PA requirement on the specific product line (e.g., enoxaparin strengths, NAYZILAM, SPRAVATO).
    • Do not dispense expecting coverage without approved PA.
    Prior Authorization

    Obtain PA for items marked 'PA' or 'SP; PA'

    Multiple drugs and drug groups are designated 'PA' or 'SP; PA' (specialty + prior authorization); providers must obtain the required prior authorization before dispensing those items.

    • When an entry shows 'SP; PA' route the request to the specialty channel and obtain PA.
    • Confirm PA is approved prior to patient administration or pharmacy claim submission.
    Prior Authorization

    Do not dispense without PA when 'PA' shown

    Any formulary entry that shows 'PA' requires prior authorization from Ambetter before coverage — providers must secure approval prior to dispensing the medication.

    • Verify the product line for a 'PA' marker and obtain authorization prior to supply.
    • Claims submitted without required PA may be denied.
    Prior Authorization

    Obtain PA for products with 'PA' noted

    Many formulary lines include 'PA' next to the drug/strength (e.g., asenapine maleate and other example entries); obtain prior authorization as indicated on the product line.

    • Check the specific strength/packaging line for PA notation.
    • Provide PA approval before submitting pharmacy claims for those strengths.
    Prior Authorization

    Use specialty channel and obtain PA for 'SP; PA' items

    Specialty products annotated 'SP; PA' require both specialty routing and prior authorization (example: FUZEON listed as 'SP; PA').

    • Submit PA and ensure specialty pharmacy fulfillment where 'SP; PA' is shown.
    • Coordinate with the specialty network per Ambetter guidance before dispensing.
    Prior Authorization

    PA required for SOFOSBUVIR‑VELPATASVIR

    SOFOSBUVIR‑VELPATASVIR tablets are listed with 'PA' — providers must request prior authorization for hepatitis C treatment with this agent.

    • Include clinical documentation supporting the hepatitis C indication when submitting PA for SOFOSBUVIR‑VELPATASVIR.
    • Do not assume coverage without approved PA.
    Prior Authorization

    Secure PA for specialty pulmonary hypertension drugs

    Several pulmonary hypertension and specialty pulmonary agents (e.g., treprostinil, epoprostenol, TYVASO kits, sildenafil/tadalafil PH products) are annotated with 'PA' or 'SP; PA' — obtain prior authorization before dispensing.

    • Submit PA and supporting clinical documentation for pulmonary hypertension agents marked 'PA' or 'SP; PA'.
    • Products with 'SP' may require specialty fulfillment in addition to PA.
    Prior Authorization

    Request PA for listed topical/systemic products

    Certain topical and systemic dermatologic products (for example halobetasol‑related entries, isotretinoin, tacrolimus) list 'PA' — providers must request prior authorization for those formulations when indicated.

    • Verify product line for PA and age limits (e.g., isotretinoin: AL(At least 12 yrs old) and PA).
    • Include patient age and indication in PA submission for topical immunomodulators and tacrolimus.
    Prior Authorization

    Obtain PA for topical agents with 'PA'

    Some topical agents such as halobetasol formulations and others are annotated with 'PA' on the formulary — obtain prior authorization when the product line indicates PA.

    • Confirm the exact formulation/strength line for the PA annotation before prescribing.
    • Provide required documentation with the PA request (age, indication, previous therapy as applicable).
    Step Therapy

    Follow step therapy where 'ST' applies

    Step therapy (ST) may apply to some products; the formulary indicates that, in applicable cases, a specified alternative must be tried before Ambetter will cover the requested agent.

    • If 'ST' appears on the product line follow the step requirement (trial of preferred alternative) before requesting PA for the subsequent agent.
    • Document prior trials when submitting an authorization if step therapy is applicable.
    Step Therapy

    Document trial of ibuprofen for ACTEMRA (ST)

    Example: ACTEMRA SOLN notes 'Must try ibuprofen: ST' — providers must document a trial of ibuprofen before the step requirement is satisfied for ACTEMRA.

    • Document prior trial of ibuprofen when requesting coverage for ACTEMRA SOLN as indicated by the 'ST' note.
    • Include trial duration and response in the PA/step documentation.
    Note
    Step Therapy

    Comply with starter‑pack and 'SP' constraints

    Some products are labeled 'SP' or appear as starter packs (e.g., ELIQUIS starter pack), indicating restricted distribution or starter‑pack rules; follow the indicated channeling/pack constraints when prescribing.

    • Route starter packs or SP‑designated products through the specialty/pharmacy channel noted by the formulary.
    • Observe per‑period max fill language (e.g., 1 max fill per 180 days for starter packs) when dispensing.
    Note

    Use tiering to guide preferred choices

    Therapeutic class tiering and tier assignments imply preferred agents (tiers 1A/1B/2/3/4); though explicit step algorithms are not provided, use tiering to guide preferred prescribing.

    • When no explicit 'ST' is shown, prefer lower‑tier agents consistent with benefit design.
    • If a higher‑tier agent is requested, be prepared to document prior trials or obtain PA if required.
    Note

    Tiering suggests preferred agents

    Tier assignments imply preferred status (lower tiers preferred); providers should consider lower‑tier alternatives first though the excerpt does not list full step rules.

    • Check the product's tier before prescribing; choose lower‑tier options when clinically appropriate.
    • If prescribing higher‑tier drugs, expect potential PA or justification requirements.
    Step Therapy

    Adhere to 'ST' when shown

    Where a product line shows 'ST' (step therapy), such as for some antiparkinson agents, providers must follow the step requirement (trial of the specified alternative) prior to approval.

    • Document the required prior therapy when submitting an authorization for agents marked 'ST'.
    • Failure to document prior trial may lead to denial or request for additional information.
    Note

    No explicit step algorithm in excerpt — follow tiers and PA

    The excerpt does not provide a complete step‑therapy algorithm; when 'ST' is not specified, follow documented tier preference and PA processes.

    • If no explicit step sequence is listed, rely on tier preference and be prepared to provide prior therapy documentation if PA is requested.
    • Consult full policy or pharmacy helpdesk for complete step therapy rules if uncertain.
    Note

    Step therapy details not specified here — verify with payer

    No explicit step therapy sequencing text is included in this extract; providers must refer to product lines for any 'ST' flags and to the payer for full step policy details.

    • When 'ST' is shown on a product line, include documentation of prior trial(s) with the PA or step submission.
    • Contact Ambetter for the complete step‑therapy algorithm if needed.
    Step Therapy

    Follow 'ST' for listed topical products

    Step therapy applies to specified products in the extract (examples include clindamycin/tretinoin and multiple corticosteroid entries marked 'ST'); follow the step requirement where shown.

    • Document prior use of required alternative agents when requesting authorization for 'ST'‑flagged topical products.
    • Include age and prior treatment details as required.
    Note

    Tiering implies preference; verify 'ST' where applicable

    Tier assignments imply preferred agents but do not replace explicit step requirements; verify 'ST' flags on product lines when applicable.

    • If a product is higher tier, expect PA or step documentation may be required.
    • Confirm any 'ST' note on the exact formulation line before submitting PA.
    Documentation Required

    Submit PA with required documentation; note 24/72‑hour turnarounds

    Providers must complete the Prior Authorization form and submit necessary clinical information; urgent requests will be answered within 24 hours and non‑urgent within 72 hours once all information is received.

    • Submit completed PA form with supporting clinical documentation to avoid delays.
    • Expect disapproval notices to state reasons or identify missing material information if the request is incomplete.
    Documentation Required

    Document prior fills and package/fill‑intervals for PA requests

    Formulary entries show quantity limits and package/fill‑interval language (e.g., package(s) per 180 days) — providers should document fill history and relevant dispensing intervals when submitting PA.

    • Include prior fill history and justification when requesting exceptions to package or per‑period limits.
    • Reference the exact per‑period limits from the product line in the PA request.
    Documentation Required

    Document justification when requesting >7‑day opioid supply

    When requesting authorization for opioid prescriptions exceeding new‑start limits, prescribers should document clinical justification for longer supplies — new starts are limited to a 7‑day supply per the formulary.

    • Document rationale and prior therapy when requesting PA for opioid supplies beyond the 7‑day new‑start limit.
    • Be aware policy permits up to two 7‑day fills in any 28‑day period and up to 28 non‑consecutive days in 90 days (per thresholds).
    Documentation Required

    Include clinical justification for PA requests that seek QL overrides

    Many product entries pair PA or SP flags with quantity limits (QL); when PA/QL are shown, include clinical justification for the requested quantity and dose in the PA submission.

    • Provide diagnosis, prior therapies, and rationale for requested quantity when submitting PA for QL‑restricted products.
    • Ensure claims reflect the QL/PA annotations to avoid rejection.
    Billing Rule

    Ensure claims reflect QL and PA on approved authorizations

    Pharmacy claims must reflect the formulary's QL and PA indicators; providers should ensure claim submissions include authorization identifiers and match the approved quantity/intervals.

    • Include the PA approval number on the claim and adhere to approved quantity limits.
    • Claims with quantities exceeding QL or missing required PA may be denied.
    Documentation Required

    Document patient age and indication for AL‑restricted drugs

    When a product has an Age Limit (AL) shown (for example isotretinoin, XIFAXAN entries), providers must document the patient's age and indication in the PA or claim.

    • Include patient age and the clinical indication in the PA request for AL‑restricted products.
    • Verify member meets the AL before dispensing or submitting the claim.
    Documentation Required

    Provide supporting clinical documentation for PA/QL requests

    For PA or QL requests, providers must supply supporting clinical documentation that justifies the requested quantity or dose (for example prior treatment history or clinical rationale).

    • Attach prior therapy records, relevant labs, and treatment rationale to the PA submission.
    • Insufficient documentation may lead to disapproval or request for additional information.
    Documentation Required

    Document fill‑intervals when requesting QL exceptions

    Quantity limits and fill‑interval language are enforced (examples: 1 max fill per 90/180 days, QL per fill/period); providers should document dispensing intervals when requesting exceptions or PA.

    • Cite prior fill dates and quantities when asking for exceptions to max‑fill rules.
    • Use the formulary's stated per‑period limits in the PA justification.
    Documentation Required

    Provide documentation for SP/PA injectable products

    Specialty (SP) and PA flags on injectable or infusion products indicate restricted distribution and require supporting documentation with PA submissions and routing through specialty channels as indicated.

    • When 'SP' appears, coordinate with the specialty pharmacy network and include necessary supporting documents with the PA.
    • Some infusion/injectable products require both SP routing and PA prior to coverage.
    Documentation Required

    Document age and quantity compliance for AL/QL products

    Age and quantity limits are enforced for multiple products (examples: pimecrolimus AL(At least 2 yrs); tacrolimus OINT AL + PA); providers must document age and QL compliance in PA requests.

    • Confirm patient meets AL before submitting PA or dispensing.
    • Include age and prior treatment details in the PA when AL or QL is listed.
    Note
    Denial Risk

    Expect specific reasons on PA denials

    If a prior authorization request is disapproved, the disapproval notice will state specific reasons for the denial or identify missing material information required to complete the request.

    • Review the notice to determine whether additional information can cure the denial.
    • Submit missing material information promptly when identified.
    Denial Risk

    Claims may be denied for specialty drugs without PA

    Claims for specialty agents may be denied if PA is not obtained when indicated (many specialty biologics and injectable products show 'PA' or 'SP; PA').

    • Obtain PA prior to dispensing specialty biologics to avoid claim denials.
    • Verify specialty routing requirements and PA approval before patient administration.
    Denial Risk

    QL exceedance can trigger denials

    Exceeding a product's quantity limit (QL) can trigger denial or require a prior authorization; document prior therapy and justification when requesting quantities beyond the QL.

    • Do not submit claims exceeding QL without an approved PA.
    • Include relevant clinical rationale and prior use when seeking QL exceptions.
    Denial Risk

    PA/QL/new‑start limits may trigger denials

    Entries marked with PA and/or those that exceed quantity or new‑start limits (e.g., new starts limited to 7 days) may trigger denials or require additional review; obtain PA where indicated.

    • For new‑start opioid fills beyond 7 days, submit PA with supporting justification.
    • If PA is required and not obtained, expect the claim to be denied or returned for review.
    Denial Risk

    Missing PA/SP or exceeding QL risks denial

    Formulary flags 'PA', 'SP', and explicit QL or max‑fill per period are common denial triggers — missing required PA or exceeding limits may cause claim denial or noncoverage.

    • Before dispensing, verify whether the product line shows 'PA' or 'SP' and obtain approvals.
    • Confirm the dispensed quantity and fill interval conform to formulary limits to avoid denials.
    Prior Authorization

    Obtain PA for enoxaparin strengths showing 'PA'

    Multiple enoxaparin presentations are annotated with 'PA' — providers should obtain prior authorization for the listed enoxaparin strengths to avoid coverage denial.

    • Check the exact enoxaparin strength/format for a 'PA' notation and secure authorization before dispensing.
    • Claims for enoxaparin may be denied if PA is not in place.
    Prior Authorization

    Secure PA for CNS/rescue agents flagged 'PA'

    Several CNS/rescue medications (examples: NAYZILAM, VALTOCO, SPRAVATO) are flagged with 'PA' — dispensing without prior authorization risks claim denial.

    • Verify PA is approved before dispensing NAYZILAM, VALTOCO, or SPRAVATO formulations that show 'PA'.
    • Include quantity limit compliance and indication in the PA to reduce denial risk.
    Prior Authorization

    PA or SP; PA markers require prior authorization

    Formulary entries that display 'PA' or 'SP; PA' indicate prior authorization or specialty prior authorization requirements; failure to obtain required authorization may lead to claim denial.

    • When the product line shows 'PA' or 'SP; PA', do not assume coverage without documented authorization.
    • Follow specialty routing and documentation procedures for SP; PA items.
    Denial Risk

    QLs are enforceable — request PA for exceedance

    Quantity limits shown on product lines (examples: QL(4 EA daily; 40 EA per fill), QL(3 EA daily)) are enforceable utilization limits — requests exceeding these limits require PA or may be denied.

    • Review the product's QL before prescribing and document justification when seeking exceedance.
    • Include prior dispensing records in PA to support requests above QL.
    Denial Risk

    Missing PA/SP may lead to denials

    If PA or specialty pharmacy requirements are not met for products that list 'PA' or 'SP; PA', requests may be denied — verify and obtain necessary approvals prior to dispensing.

    • Confirm and document PA/SP requirements on the exact product line before filling.
    • Denials for missing PA/SP can be appealed with supporting clinical information if appropriate.
    Note
    Note
    Note
    Note
    Note

    Initial Therapy Limits & Guidance

    Initial therapy limits

    Initial prescribing restrictions noted in the formulary for certain product classes.

    New start supply limits: Many opioid-containing and select injectable/other products specify 'New starts limited to 7 day supply' as an initial therapy restriction.7 day(s)

    Applies to initial prescriptions unless Prior Authorization is obtained.

    Initial therapy examples

    Examples of initiation utilization constraints observed in the formulary.

    Asenapine maleate example: Asenapine maleate (2.5 mg, 5 mg, 10 mg) entries include Quantity Limits (e.g., QL(2 EA daily) for some strengths) and are marked PA on select strengths, indicating PA is required for coverage beyond standard limits.per-product QL as listed

    This is an example of how initial QL and PA modifiers are applied in the formulary.

    Carbidopa-levodopa example: Carbidopa-levodopa formulations are assigned Tier 1B with QL examples (e.g., QL(2 EA daily)) and may include age limits on some presentations.per-product QL as listed

    Serves as an example of tier + QL application for chronic therapy agents.

    Topical steroid initial therapy guidance

    Topical corticosteroid and related topical agents are tiered and include initial quantity limits.

    Topical steroid formulary entries: Topical corticosteroid formulations are assigned tiers (commonly Tier 1B) and include per-product quantity limits (examples: QL(3 GM daily), QL(3.5 GM daily), QL(4 GM daily)); some formulations also show PA requirements.per-product QL values (GM or ML daily)

    Prescribers should follow listed QL and obtain PA when indicated for topical steroids.

    Step Therapy Requirements

    Step therapy summary
    Step therapy (ST) may require trying alternative drugs before coverage of certain agents; example: lisdexamfetamine dimesylate entries show ST noted alongside QL (e.g., QL(1 EA daily); ST)
    Step therapy example
    ACTEMRA SOLN entry references quantity limits per 28 days and notes 'Must try ibuprofen: ST' (step therapy requiring trial of ibuprofen prior to coverage)
    Tier-implied step therapy
    Formulary assigns drugs to tiers (examples include Tier = 1A, 1B, 3, 4). These tier assignments imply preference for lower-tier agents and may result in required trials of lower-tier alternatives, although explicit step sequences are not provided in the excerpt.
    Starter pack and SP constraints
    Some products appear as starter packs or carry an 'SP' (specialty) flag; e.g., ELIQUIS DVTIPE STARTER PACK and XARELTO STARTER PACK entries list fill limits (1 max fill per 180 days or per-year language) and SP designations, indicating restricted distribution or starter-pack constraints.
    Tier assignments
    Multiple entries show tier designations (examples: 1A, 1B, 3, 4). Tiering indicates formulary preference but the excerpt does not provide full step-therapy sequences tied to those tiers.
    ST flagged entries
    Some antiparkinson and related therapy entries include the 'ST' annotation (e.g., antiparkinson drug groups show QL values plus 'ST'), indicating step therapy may apply to these agents.
    Explicit step-therapy steps present?
    The excerpt contains tiering and 'ST' flags for select products but does not list explicit multi-step progression rules or full step-therapy algorithms for members/providers to follow.
    Excerpt scope on step therapy
    No explicit step therapy step-by-step instructions are shown in this formulary excerpt; entries are limited to tier, QL, PA, SP, and occasional 'ST' annotations.
    Topical products with ST
    Several topical formulations list 'ST' (step therapy) — examples include clindamycin phosphate‑tretinoin and multiple topical corticosteroid entries (corticosteroids/topical agents show ST on some lines), indicating step requirements apply to selected topical therapies.
    Tier designations (examples)
    Formulary examples show tier assignments such as Tier = 1B and Tier = 3 for multiple agents (topical and systemic); specific step-therapy sequences are not provided alongside these tier designations.

    Quantity Limit Examples and Enforcement

    Multiple stimulant/ADHD products — QL examples for stimulants and ADHD products
    Multiple stimulant/ADHD QLsExamples include QL(1 EA daily); QL(2 EA daily); QL(3 EA daily); QL(280 ML per 56 days)
    Patch and chewable examplesmethylphenidate PTCH: QL(1 EA daily); methylphenidate CHEW: QL values vary (e.g., 6 EA daily)
    Age limits with stimulantsAL(At least 6 yrs old) commonly paired with many stimulant formulations
    ADALIMUMAB presentations — QL and package-per-period examples
    Adalimumab QL and package limitsQL(0.143 EA daily); package(s) per 180 day(s) retail/mail; PA indicated for many presentations
    Starter/limited fills1 max fill(s) per 180 day(s) retail for certain starter kits (per entry notes)
    PA requirementMany adalimumab presentations include PA alongside QL/package limits
    ACTEMRA SOLN — QL examples per 28 days retail/mail
    ACTEMRA SOLN QL examplesQL(3.6 ML per 28 day(s) retail; 4 ML per 28 days mail) and QL(20 ML per 28 day(s)) — ACTEMRA SOLN/ACTPEN entries
    ACTEMRA SOLN 200ACTEMRA SOLN 200: QL(40 ML per 28 day(s) retail; 40 ML per 28 days mail); SP; PA
    Step therapy noteSome ACTEMRA ACTPEN entries reference 'Must try ibuprofen: ST'
    naproxen sodium TABS 550 MG — QL(6 EA daily) example
    Naproxen sodium 550 mg QLQL(6 EA daily)
    Suspension QLNaproxen SUSP entries may be PA; QL(6 EA daily) shown for some suspensions
    Related analgesic entriesSeveral NSAID entries list daily EA QLs (e.g., oxaprozin QL(6 EA daily))
    OTEZLA TABS — QL and TBPK example
    OTEZLA tablets QLQL(2 EA daily); TBPK: 1 package per 180 day(s) retail — OTEZLA examples
    OTEZLA age bandAL(At least 45 yrs old Up to 79 yrs old) appears with some OTEZLA entries
    PA flagPA indicated for OTEZLA TBPK in entry
    ENBREL SURECLICK SOAJ — QL examples
    ENBREL SURECLICK QLQL(0.146 ML daily) — ENBREL SURECLICK SOAJ example
    ENBREL SOLN new-start noteNew starts limited to 7 day supply noted for some ENBREL entries
    PA indicatorPA shown for several ENBREL presentations
    multiple opioid products — assorted QL examples for opioids and injectables
    Opioid QL assortmentExamples across opioid-containing products: QL(2 EA daily); QL(0.146 ML daily); QL(50 ML daily); QL(12 EA daily); QL(6 EA daily)
    New-start restriction recurringMany opioid and opioid-containing entries include 'New starts limited to 7 day supply'
    PA often appliedPA is frequently listed alongside QL for opioid products (claims may be denied without PA)
    ANDROGENS-ANABOLIC example — QL per fill and max fill per period
    Androgens/ivermectin exampleQL(9 EA per retail; 9 per fill mail); 1 max fill(s) per 75 day(s) retail — example shown in androgens/anabolic grouping
    Androderm patch QLQL(1 EA daily); PA for transdermal androgen examples
    PA presenceSome entries in this group include PA as a requirement
    alprazolam (various strengths) — QL examples and concentration-based QL
    Alprazolam QL examplesQL(4 EA daily) for some oral tablet strengths; concentration-based QL examples for injectable/conc forms (e.g., QL(0.036 ML daily))
    Benzodiazepine product variationDifferent formulations (tabs, concentrates, solutions) show different QL metrics (EA vs mL)
    PA may applyPA flags appear on select benzodiazepine/formulation entries
    ELIQUIS DVTIPE STARTER PACK — starter pack QL/limit example
    ELIQUIS starter pack limit1 max fill(s) per 180 day(s) retail — ELIQUIS DVTIPE STARTER PACK example
    Xarelto tablet QLQL(2 EA daily) — XARELTO TABS 15 MG example
    Rivaroxaban suspension large QLQL(900 ML per 30 day(s) retail; 900 ML per 30 days mail)
    rivaroxaban suspension — large-volume QL example
    Rivaroxaban suspension QLQL(900 ML per 30 day(s) retail; 900 ML per 30 days mail) — large-volume suspension example
    Xarelto tablet exampleQL(2 EA daily) — XARELTO TABS 15 MG
    Starter pack periodStarter pack entries may also include per-year or per-period limits (e.g., 365 day(s) for starter packs)
    enoxaparin sodium SOLN IJ 300 MG/3ML — QL(6 ML daily)
    Enoxaparin 300 mg/3 mL QLQL(6 ML daily) — enoxaparin sodium SOLN IJ 300 MG/3ML
    Enoxaparin SOSY strengthsQL(2 ML daily) — enoxaparin SOSY 100 MG/ML and 150 MG/ML examples
    Per-fill/strength variationDifferent vial sizes and strengths show differing QL and SP/PA flags
    EMVERM CHEW (albendazole) — per-fill limits and max fill interval
    EMVERM CHEW per-fill limits6 EA per fill retail; 6 per fill mail; 1 max fill(s) per 60 day(s) retail
    Albendazole PA noteSome anthelmintic entries include PA for specific uses
    TieringEMVERM CHEW appears Tier = 2 (per extract) with QL and max-fill per period
    XARELTO TABS 15 MG — QL example (2 EA)
    XARELTO 15 mg tablet QLQL(2 EA daily)
    Tier infoXARELTO TABS 15 MG shown in Tier = 2 in extract
    Starter/pack notesStarter pack and SP/PA flags present for related anticoagulant entries
    enoxaparin sodium SOLN IJ 300 MG/3ML — QL example (6 ML)
    Enoxaparin 300 mg/3 mL QL repeatQL(6 ML) — enoxaparin SOLN IJ 300 MG/3ML (daily) example
    Enoxaparin SOSY rangesMultiple SOSY vial sizes with QL per-day values (0.6 ML, 0.8 ML, 1.6 ML, etc.)
    PA/SP flagsSome enoxaparin presentations show PA and/or SP designations
    enoxaparin sodium SOSY 100 MG/ML, 150 MG/ML — QL example (2 ML)
    Enoxaparin SOSY 100/150 mg QLQL(2 ML daily) — enoxaparin sodium SOSY 100 MG/ML, 150 MG/ML example
    Fondaparinux per-180-day QLQL(7.2 ML per 180 day(s)) also listed for fondaparinux 10 MG/0.8 mL
    PA indicatorPA noted for several parenteral anticoagulant presentations
    fondaparinux sodium 10 MG/0.8ML — QL per 180 days example
    Fondaparinux 10 mg/0.8 mL QLQL(7.2 ML per 180 day(s)) (also listed as ~7 ML per 180 days in mail/retail entries)
    Per-180-day interpretationRepresents cumulative permitted volume over 180-day period for that presentation
    PA may applyPA shown for some fondaparinux entries
    NAYZILAM — QL(10 EA per 30 days)
    NAYZILAM QLQL(10 EA per 30 days) — NAYZILAM (midazolam) nasal formulation
    PA and ST notesNAYZILAM entries include PA; some seizure rescue products reference ST or package limits
    Per-30-day packagingPer-fill and per-30-day limits applied to rescue agent formulations
    VALTOCO 15 MG DOSE — QL example (60 ML daily)
    VALTOCO 15 mg dose QLQL(60 ML daily) — VALTOCO 15 mg dose entry
    Multiple dosing formsVALTOCO presented in multiple dose forms with differing QL values (10 EA per 30 days; 40 ML daily etc.)
    PA flag possibilityPA is present on some rescue/CNS entries in adjacent extract lines
    vancomycin hcl CAPS — QL(4 EA daily; 40 EA per fill retail)
    Vancomycin capsule QLQL(4 EA daily; 40 EA per fill retail)
    Per-fill aggregationPer-fill caps limits shown in addition to daily EA limits
    TieringVancomycin entries appear Tier = 1B in extract
    XIFAXAN 200 MG — QL per treatment course example
    XIFAXAN 200 mg course QLQL(3 EA per 3 day(s) retail; 9 EA per 3 days mail) — rifaximin 200 mg treatment-course example
    Age and PAAL(At least 12 yrs old); PA indicated for XIFAXAN entries
    Treatment course framingQL specified per 3-day treatment course (retail/mail differences)
    atovaquone-proguanil hcl — QL(12 EA per fill) and 1 fill every 180 days limit
    Atovaquone-proguanil QL and fill limitQL(12 EA per fill retail; 12 per fill mail); Limit 1 fill every 180 days — covered for malaria treatment only
    Covered-for-only indicationExplicit statement: 'Covered for malaria treatment only' accompanies fill/QL limits
    PA may applyPA appears in some atovaquone-proguanil entries in extract
    hydroxychloroquine sulfate 200 MG — QL(3 EA daily)
    Hydroxychloroquine 200 mg QLQL(3 EA daily)
    Strength variants400 mg entries also present with different QL metrics (in extract QL(T EA daily) noted)
    TieringHydroxychloroquine entries shown Tier = 1B in excerpt
    RUXIENCE — QL(0.0089 EA daily)
    RUXIENCE QLQL(0.0089 EA daily) — RUXIENCE (biosimilar) example
    SP/PA flagsRUXIENCE listed with SP; PA in extract — specialty/biosimilar handling noted
    Small per-day EA metricVery small EA/day values used for high-cost biologic dosing (0.0089 EA daily)
    TAGRISSO 40 MG — QL(2 EA daily)
    TAGRISSO 40 mg QLQL(2 EA daily)
    PA/SP contextTAGRISSO entries show SP; PA for some strengths in adjacent extract lines
    Antineoplastic dosingDaily EA limits typical for oral antineoplastics in listing
    abiraterone acetate 250 MG — QL(4 EA daily)
    Abiraterone acetate 250 mg QLQL(4 EA daily)
    500 mg variantAbiraterone 500 mg listed with QL(2 EA daily) and PA for some entries
    PA/SP flagsSome hormonal antineoplastic entries include PA and SP designations
    XTANDI TABS 40 MG — QL(4 EA daily)
    XTANDI 40 mg QLQL(4 EA daily); PA indicated
    80 mg variantXTANDI TABS 80 MG show QL(2 EA daily) in extract
    SP/PA presenceHigh-cost oncology oral agents often accompanied by PA/SP flags
    ALECENSA — QL(8 EA daily)
    ALECENSA QLQL(8 EA daily); PA indicated
    Antineoplastic handlingALECENSA appears with PA and per-day EA limits consistent with oncology agents
    Related PA notePA shown in the extract for ALECENSA entries
    PIQRAY (200 MG) — QL(1 EA daily)
    PIQRAY 200 mg QLQL(1 EA daily); PA indicated
    Higher-dose variantsPIQRAY 250/300 mg show higher QL per day and SP/PA flags in extract
    Antineoplastic class notePIQRAY entries are Tier = 4 and subject to PA
    ZELBORAF — QL(8 EA daily) and vinorelbine example
    ZELBORAF QLQL(8 EA daily); SP; PA — ZELBORAF example
    Vinorelbine QLQL(4 EA daily) — vinorelbine tartrate 10 mg/mL example
    SP/PA common in oncologyMany antineoplastic entries include SP and PA flags
    Multiple (various entries) — compiled QL examples and fill-interval limits
    Compiled QL and fill-interval examplesExamples include QL(1 EA daily), QL(2 EA daily), QL(6 EA daily), QL(30 ML daily), QL(0.036 ML daily); fill-interval limits such as 1 max fill per 90 or 180 days
    Labetalol QL varianceQL(1 EA daily) or QL(8 EA daily for 300 mg formulation) shown in extract
    SKYRIZI pen topical/biologic QLQL(20 GM daily) — SKYRIZI PEN SOAJ example
    labetalol (various strengths) — QL examples (1 EA daily; 8 EA daily)
    Labetalol tablet QL examplesQL(1 EA daily) typical; some 300 mg listing shows QL(8 EA daily)
    Beta-blocker daily limitsMultiple beta-blocker entries show QL(1 EA daily) or QL(2 EA daily) depending on strength/formulation
    Formulation-specific variationSome entries list both daily EA limits and per-fill higher limits for specific strengths
    HEMANGEOL SOLN PO, sildenafil/tadalafil examples — assorted QL values
    Hemangeol / PH solution QLsQL(75 ML) — HEMANGEOL SOLN PO; QL(37.5 ML daily) or QL(6 ML daily) for sildenafil/tadalafil PH solutions
    Treprostinil / prostacyclin QL/PAtreprostinil SOLN IJ: SP; PA — specialty injectables often require PA
    Prostaglandin vasodilator QLExamples include QL(2 EA daily) with PA indicated for several formulations
    clindamycin phosphate - benzoyl peroxide gel — topical QL example
    Clindamycin/benzoyl peroxide gel QLQL(15 GM per 30 day(s) retail/mail) and AL(At least 12 yrs old); PA may apply
    Isotretinoin QLQL(60 GM per 30 day(s) retail; 60 GM per 30 days mail); AL(At least 12 yrs old); PA
    Betamethasone dipropionate topical QLsQL(3 GM daily); QL(3.34 ML daily); QL(3.5 GM daily) across oint/cream/lotn forms
    isotretinoin 10/20 MG — QL(60 GM per 30 days) and topical examples
    Isotretinoin and acne topical age/QLAL(At least 12 yrs old); QL(60 GM per 30 days) for isotretinoin and many acne topicals
    Clotrimazole topical fill limitQL(4.5 GM daily); Limit 1 Fill per 180 days; 1 max fill(s) per 180 day(s) retail
    Immunomodulators topicalPimecrolimus: QL(3 GM daily); AL(At least 2 yrs old); Tacrolimus OINT: AL(At least 2 yrs old); PA
    clotrimazole (topical) and multiple topical examples
    Topical QL collectionExamples include QL(4 GM daily); QL(3 GM daily); QL(6 ML daily); QL(2 GM daily)
    Halobetasol and halcinonideHalobetasol propionate CREA: QL(3.5 GM daily); Halcinonide CREA: PA may apply
    Imiquimod QLQL(12 EA per fill retail; 12 per fill mail) — imiquimod 5%
    Examples of quantity limits — further topical & related examples
    Imiquimod QL and fillsQL(12 EA per fill retail; 12 per fill mail) — imiquimod 5%
    Pimecrolimus/tacrolimus age limitsAL(At least 2 yrs old) — pimecrolimus and tacrolimus topical ointment entries; PA required for tacrolimus
    Lidocaine PRSY periodlidocaine hcl PRSY: 365 day(s) — annual period limit
    Formulary abbreviations and definitions
    PA definitionPA = Prior Authorization. Your doctor must ask for approval from Ambetter before some drugs will be covered.
    QL definitionQL = Quantity Limit. Some drugs are only covered for a certain amount (specified as EA daily, ML daily, per fill or per period).
    AL definitionAL = Age Limit. Some drugs are only covered for certain ages.

    Specialty, Infusion & Fulfillment Notes

    Billing Rule

    Route specialty‑tier drugs to participating specialty/hemophilia pharmacies

    Some infusion/ specialty‑tier drugs must be fulfilled at participating specialty or hemophilia network pharmacies; providers should route such prescriptions accordingly.

    • Use Ambetter's specialty/hemophilia network for fulfillment when the product is specialty‑tier.
    • Check Ambetter pharmacy information for network participation.
    Documentation Required

    Coordinate PA and specialty handling for injectable/infusion products

    Injectable/infusion products marked 'PA' and 'SP' indicate restricted distribution or specialty handling; obtain PA and coordinate specialty fulfillment before administration.

    • Coordinate PA approval with the specialty pharmacy and confirm handling/fulfillment requirements.
    • Do not schedule infusion/administration until PA and specialty routing are confirmed.

    Formulary Abbreviations & Definitions

    QL — Quantity Limit definition and example
    QL (Quantity Limit) explainedQuantity Limit as listed (e.g., QL(3.6 ML per 28 day(s) retail)) — maximum allowed quantity per specified time period
    Examples in contextCan be expressed per day (EA daily), per fill, or per period (per 28/30/180 days) depending on product entry
    Claims implicationQL markers must be reflected on pharmacy claims; exceedance may trigger denial or require PA
    PA — Prior Authorization definition and requirements
    PA (Prior Authorization) definitionPrior Authorization: Your doctor must request approval from Ambetter before some drugs will be covered; non-formulary drugs require provider-completed PA form with 24/72 hr response times for urgent/non-urgent requests once complete.
    Denial explanationIf a prior authorization request is disapproved, the notice will include a clear explanation of the reasons for disapproval or identify missing material information.
    PA impactProducts marked 'PA' may be denied at claim if authorization not obtained prior to dispensing
    New starts limited to 7 day supply — definition and application
    New-start supply definitionNew starts limited to 7 day supply — initial prescriptions limited to a 7-day supply unless otherwise authorized
    Allowed repeatsAllow up to two 7-day fills during any 28-day period; up to 28 non-consecutive days in any 90-day period
    PA for exceeding limitsFills exceeding these new-start limits require Prior Authorization

    Background & Scope

    Background: this excerpt is a partial Ambetter formulary listing (Ambetter Formulary Updated January 2026). It displays drug classes and individual products with assigned tiers and per‑product utilization controls. The listing format shows copay tiers, quantity limits (QL), prior authorization (PA) and age limits (AL), and notes that the formulary is a guide—not a complete catalog of covered products. Specialty drugs may require fulfillment through specialty or hemophilia network pharmacies and initial‑therapy constraints (for example, opioid new‑start limits) are included where applicable.